Simplify Logo

Full-Time

Sr/Scientist

Ffpe Rna

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Hardware
Biotechnology
Healthcare

Compensation Overview

$108.8k - $163.1kAnnually

Mid, Senior

San Carlos, CA, USA + 1 more

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in molecular biology, biochemistry, or closely related field with 6 years experience in assay development for the life science industry.
  • Master’s degree in molecular biology, biochemistry, or closely related field with 3 years experience in assay development for the life science industry.
  • Doctorate in molecular biology, biochemistry, or closely related field with 0-2 years experience in assay development for the life science industry.
  • Expertise in RNA biology.
  • Proven track record of developing production-grade assays for RNA quantification and sequencing.
  • Strong understanding of the chemistry underlying nucleic acid extraction, PCR, NGS library preparation, hybrid capture, and sequencing technologies.
  • Demonstrated success with cross-functional collaborations.
  • Must have experience with various molecular biology techniques including but not limited to: next generation sequencing, PCR/qPCR, and nucleic acid extraction and quantification.
  • Must be capable of independently planning complex studies, manually executing experiments in the lab, interpreting results, and making data-driven decisions.
  • Must have experience in optimizing laboratory protocols, identifying risks, and troubleshooting issues.
  • Must have good organization and time management skills.
  • Must have experience performing statistical analyses in Excel or similar software.
  • Must be familiar with bioinformatics software commonly used in RNA-sequencing analysis (STAR, samtools, DESeq2, etc.).
  • Must have experience working in a regulated laboratory environment.
Responsibilities
  • Build high-throughput RNA-sequencing assays from extraction to sequencing.
  • Explore the feasibility of emerging technologies in the RNA-sequencing field.
  • Design and execute studies, analyze and interpret data, decide on next steps, and communicate findings to other scientists.
  • Collaborate with bioinformaticians, computational biologists, and software engineers to develop analysis pipelines.
  • Collaborate with automation engineers to scale and robustify assays.
  • Collaborate with laboratory directors, clinical lab scientists, and quality engineers to produce production-ready protocols.
  • Perform other duties as assigned.

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology, cell-free DNA (cfDNA) testing, analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care through accurate genetic insights and early detection of health issues.

Company Stage

IPO

Total Funding

$1.2B

Headquarters

Austin, Texas

Founded

2004

Growth & Insights
Headcount

6 month growth

8%

1 year growth

20%

2 year growth

52%
Simplify Jobs

Simplify's Take

What believers are saying

  • Natera's continuous innovation, such as the launch of the Prospera Heart test with DQS, demonstrates its commitment to improving patient outcomes and maintaining market leadership.
  • The company's diverse product offerings across oncology, transplant health, and women's health provide multiple revenue streams and reduce dependency on a single market.
  • Significant investments from entities like Massachusetts Financial Services Co. MA indicate strong financial backing and confidence in Natera's growth potential.

What critics are saying

  • Allegations of deceptive sales and billing practices could damage Natera's reputation and lead to legal and financial repercussions.
  • The highly competitive nature of the genetic testing market requires constant innovation and differentiation to maintain market share.

What makes Natera unique

  • Natera's focus on cell-free DNA (cfDNA) technology for a wide range of applications, from oncology to prenatal screening, sets it apart from competitors who may specialize in only one area.
  • The introduction of unique features like the Donor Quantity Score (DQS) for transplant rejection detection enhances the accuracy and reliability of their tests, distinguishing them from other genetic testing companies.
  • Natera's extensive portfolio of over 200 peer-reviewed publications underscores its commitment to scientific validation and credibility, which is a significant competitive advantage.

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks